Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04054141
Other study ID # 2018-0434
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 1, 2018
Est. completion date August 16, 2022

Study information

Verified date November 2022
Source Hospital for Special Surgery, New York
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label clinical trial to determine the safety and efficacy of rTMS in reducing spasticity and improving quality of life among patients with upper motor neuron predominant motor neuron disease (MND).


Description:

The study's objective is to evaluate the role of rTMS for symptom reduction of spasticity among patients with upper motor neuron predominant motor neuron disease. This study is 12-week open label safety and efficacy trial. A total of 10 subjects with PLS and UMN/ MND will be enrolled in this study.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date August 16, 2022
Est. primary completion date August 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Age = 18, men or woman - Diagnosis of upper motor neuron predominant ALS, which also includes patients with primary lateral sclerosis (PLS), as defined as only upper motor neuron features in at least 2 body segments. - EMG within 3 months of enrollment with minimal or no evidence of lower motor neuron disease. - Time from symptom onset > 18 months - On a stable dose of, or has not taken, Riluzole for at least thirty days. - Has not taken, or has received at least 2 cycles of dosing of, Edaravone prior to screening. - Able to communicate clearly the desire to withdraw from the procedure at any stage. - Impaired walking as measured by a Hauser Ambulation index of greater than 1 and less than 7 (2 to 6, inclusive). - MMSE = 22 and deemed by the PI as being capable of providing informed consent and following trial procedure. - Has spasticity, equal or above 1 in the Ashworth Scale for spasticity in 2 or more muscle group of at least 3 months duration. - Absence of exclusion criteria. Exclusion criteria - Patient has a history of drug or alcohol abuse within the past year; - Patient has clinically significant abnormal laboratory values. - Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity - Received Botulinum Toxin during the preceding 6 months - Bedridden and patients with tracheostomy. - Fixed-tendon contractures - Poorly controlled epilepsy or recurrent seizures (Subjects who have had one or more seizures in the year prior to Visit 1 will be excluded) - Unable to provide an informed consent - Unable to comply with the procedures - Unable to communicate clearly if the subject wants to withdraw from the procedure at any stage - History of brain surgery for any indication - Has pacemaker, cochlear implants, brain stimulators, infusion pumps, intracardiac lines, metallic clips, other implanted electronic or ferroelectric metallic devices above the neck (Dental implants are permitted), piercing or body modification above the neck, known history of TMS related complications or side effects. - MMSE <22. - Female patients of child bearing period who are not practicing contraception. - Female patients who are pregnant. - Inability to perform either rTMS due to insufficient MEP amplitude (< 50 µv).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Mag Stim
rTMS

Locations

Country Name City State
United States Shara Holzberg New York New York

Sponsors (1)

Lead Sponsor Collaborator
Hospital for Special Surgery, New York

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary safety of rTMS in subjects with PLS/UMN/MND. Number of participants with treatment related AE's will be measured with stringent stopping rules and reported. We hypothesize that no serious treatment related adverse event. Transcranial magnetic stimulation is a non-invasive procedure used to stimulate small regions of the brain. The effect of rTMS on spasticity was studied in patients with stroke, MS, SCI and CP and found to be safe (4). There are no studies assessing safety of rTMS in patients with PLS and UMN/ MND with spasticity. Because it is so well tolerated in other diseases, we anticipate no adverse effects. However, we will systematically assess all adverse effects with stringent stopping rules for individual patients and the study. We hypothesize that no patient will have a serious treatment related adverse event. Therefore we will track the number of Participants With Treatment-Related AE as Assessed by CTCAE v4.0 from week 0 to the end of the study, an average of 5 months.
Secondary To evaluate efficacy of rTMS using a modified FDA approved protocol in research subjects with PLS and UMN/MND. The secondary objective of this study is to determine if rTMS causes an improvement in walking speed in patients with PLS and UMN/MND. This will be determined by evaluation of subject's walking speed during treatment and for period after the rTMS stimulation series has stopped. The primary end point will be measured through the consistent improvement in the Timed 25 Foot walk test (T25FW). From week 0 to end of the study, an average of 5 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Completed NCT02405182 - MRI Biomarkers in ALS
Completed NCT00696332 - Talampanel for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT03865420 - Amyotrophic Lateral Sclerosis (ALS) Families Project
Recruiting NCT03272503 - A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT05568615 - Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS Phase 3
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Active, not recruiting NCT04259255 - Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02525471 - A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS) Phase 1
Recruiting NCT05031351 - NF-κB Inhibition in Amyotrophic Lateral Sclerosis Phase 2
Active, not recruiting NCT05581771 - Factors Associated With Success of NIPPV in ALS Patients
Active, not recruiting NCT03268603 - Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT05271435 - Digital Tools for Assessment of Motor Functions and Falls in ALS
Completed NCT06005506 - National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function. N/A
Recruiting NCT04138095 - Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care N/A
Recruiting NCT03698149 - ECoG BMI for Motor and Speech Control N/A
Not yet recruiting NCT05621213 - Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation N/A
Terminated NCT03373981 - Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS N/A
Completed NCT04165850 - Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS Phase 2